GLUE
Monte Rosa TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
MRT-8102 has shown deep inflammatory-biomarker reductions, MRT-2359 produced encouraging early oncology data, and cash into 2029 gives Monte Rosa time to hit multiple de-risking milestones; if one or more 2026 readouts validate, the shares could re-rate toward the 33.8 median target.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.8.
What can break
GFORCE-1 and follow-on MRT-8102 Phase 2 studies could fail to reproduce the observed inflammatory signal or raise safety concerns.
Momentum
91
Value
49
Sentiment
31
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $18.50 · Bull $33.80 · Bear $8.50
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $33.17
Why
Momentum91 · Δ7d -1.8
Value49 · Δ7d +0.2
Sentiment31 · Δ7d -7.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
91
26% active weight
Current posture
7d trendSoftening
Δ7d
-1.8
Δ21d
+15.5
Value
49
39% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
-0.0
Sentiment
31
34% active weight
Current posture
7d trendSoftening
Δ7d
-7.9
Δ21d
-1.9
Why this grade
Composite grade C. Momentum 91.4 / Value 48.9 / Sentiment 31.2
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$2B
Beta
1.61
Shares Out
84.48M
P/E (TTM)
57.5
P/S (TTM)
5.17
P/FCF (TTM)
6.47
Rev YoY
-95.0%
EPS YoY
-178.8%
Gross Margin
+80.6%
Op Margin
+4.7%
Net Debt
-$337.91M
Current Ratio
9.54
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology